Skip to content
Peptigraph home

PT-141

Melanocortin agonist. PT-141 is FDA approved for HSDD (Vyleesi); research-chemical versions are not the approved drug.

Also called:VyleesiPT141
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Strongest evidence: Human RCT evidence, 4 of 4
StatusFDA approved for HSDD (Vyleesi)Not on the WADA Prohibited ListFull legal history

Key facts

Class
Melanocortin agonist
Also called
Vyleesi, PT141
Vial sizes sold
10 mg
Community-reported sizes
Half-life
approximately 2.7 hours (range 1.9-4.0 h)
subcutaneous, in people · FDA label (Vyleesi)
FDA status
Approved for HSDD (Vyleesi)
Approved
WADA
Not listed
2026 Prohibited List
Everything on PT-141

PT-141 guides

Evidence at a glance

Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.

PT-141: studies by condition
ConditionHuman studiesAnimal studiesStudies we summarisedEvidence grade
Libido819Human RCT evidence, 4 of 4Journal of women's health 2022, PMID 35230162
MenNot in our ledgerNot in our ledger0No graded study for this goal
WomenNot in our ledgerNot in our ledger0No graded study for this goal

Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.

PT-141 is bremelanotide, and the approved version has narrow labelling

The approved product, Vyleesi, is a melanocortin receptor agonist indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder.[5]

The label states Vyleesi is not indicated for HSDD in postmenopausal women or in men.[5]

It is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease.[5]

What the trials found

Two phase 3 trials in premenopausal women found statistically significant increases in sexual desire and reductions in related distress compared with placebo.[10]

A pooled safety review reported focal hyperpigmentation was rare when dosed per label, but occurred in more than one-third of subjects after up to 16 consecutive daily doses.[11]

In men with erectile dysfunction who did not respond to sildenafil, intranasal bremelanotide gave positive clinical results in 33.5% against 8.5% on placebo.[12]

Regulatory path

FDA lists bremelanotide as an approved prescription autoinjector product; the cached record shows an original approval date of 20190621.[2]

A UK emc search for bremelanotide found no product.[13]

WADA's S0 catch-all applies only to substances with no government approval, so approved bremelanotide is outside it.[1]

Compared with

Common stacks

PT-141 is often sold pre-mixed or combined with other peptides. No controlled study has tested these combinations; the pages below cover the math and what each part has been studied for.

Common questions

Is PT-141 FDA approved?

PT-141 is FDA approved for HSDD (Vyleesi). Products sold as research chemicals are not the approved drug and are not checked by the FDA.

How much water goes in a 10 mg vial?

That choice only changes the concentration. With 2 mL, the vial is 5 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.

What is PT-141?

The approved product under the bremelanotide name is Vyleesi, a melanocortin receptor agonist.[5]

Is PT-141 for men?

The label says Vyleesi is not indicated for HSDD in men. A separate trial tested intranasal bremelanotide in men with erectile dysfunction.[5]

Is PT-141 for women?

The approved use is for premenopausal women with acquired, generalized HSDD only.[5]

Is there a PT-141 nasal spray?

Intranasal bremelanotide was tested in men with erectile dysfunction in a randomized trial.[12]

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2United States: Approved by FDA as Vyleesi (bremelanotide), Cosette, original approval 21 June 2019, for premenopausal women with acquired, generalized hypoactive sexual desire disorder (label quote).U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  3. 3FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  4. 4Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.Journal of women's health (2002) · 2022PMID 35230162Accessed 2 Oct 2026
  5. 5These highlights do not include all the information needed to use VYLEESI ® safely and effectively. See full prescribing information for VYLEESI VYLEESI (bremelanotide injection), for subcutaneous use Initial U.S. Approval: 2019FDA label (Vyleesi), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  6. 6PubMed search: bremelanotide[tiab] OR "PT-141"[tiab] OR PT141[tiab] (114 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  7. 7PubMed search: (bremelanotide[tiab] OR "PT-141"[tiab]) AND randomized controlled trial[pt] (14 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: (bremelanotide[tiab] OR "PT-141"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: (bremelanotide[tiab] OR "PT-141"[tiab] OR PT141[tiab]) AND (erectile[tiab] OR men[tiab]) (20 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.Obstetrics and gynecology · 2019PMID 31599840Accessed 2 Oct 2026
  11. 11Safety Profile of Bremelanotide Across the Clinical Development Program.Journal of women's health (2002) · 2022PMID 35147466Accessed 2 Oct 2026
  12. 12Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.The Journal of urology · 2008PMID 18206919Accessed 2 Oct 2026
  13. 13emc (UK) search: bremelanotideElectronic Medicines Compendium (UK) · 2026medicines.org.ukAccessed 2 Oct 2026

Found an error? Report a correction.